journal
MENU ▼
Read by QxMD icon Read
search

Diabetes, Obesity & Metabolism

journal
https://www.readbyqxmd.com/read/28643477/red-wine-polyphenols-do-not-improve-obesity-associated-insulin-resistance-a-randomized-controlled-trial
#1
Jorn Woerdeman, Daniele Del Rio, Luca Calani, Etto C Eringa, Yvo M Smulders, Erik H Serné
Preclinical studies have suggested that polyphenols extracted from red wine (RWPs) favorably affect insulin sensitivity, but controversy exists on whether RWPs exert similar effects in humans. This study aimed to determine whether RWPs improve insulin sensitivity in obese volunteers. Obese (BMI>30) volunteers were randomly allocated to RWPs 600 mg/day (n = 14) or matched placebo (n = 15) in a double-blind fashion (parallel-arm) for 8 weeks. Subjects were investigated at baseline and at the end of the study (EOS)...
June 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28643425/ideglira-was-effective-across-a-range-of-dysglycaemia-and-bmi-categories-in-the-dual-v-randomized-trial
#2
Ildiko Lingvay, Stewart Harris, Elmar Jaeckel, Keval Chandarana, Mattis F Ranthe, Esteban Jódar
This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine U100 (IGlar) across categories of baseline HbA1c (≤7.5%, >7.5- ≤ 8.5% and >8.5%), body mass index (BMI; <30, ≥30- < 35 and ≥35 kg/m(2) ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1...
June 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28643356/bimagrumab-improves-body-composition-and-insulin-sensitivity-in-insulin-resistant-subjects
#3
Tania Garito, Ronenn Roubenoff, Marcus Hompesch, Linda Morrow, Katherine Gomez, Daniel Rooks, Charles Meyers, Monte Buchsbaum, Srikanth Neelakantham, Therese Swan, Lee Anne Filosa, Didier Laurent, Olivier Petricoul, Marjorie Zakaria
BACKGROUND: Skeletal muscle is a key mediator of insulin resistance. Bimagrumab, an antibody against activin receptor type II (ActRII), prevents binding of negative muscle regulators, like myostatin, and increases lean mass and decreases fat mass in animal models. OBJECTIVE: We hypothesized that an improving body composition in insulin resistant individuals could enhance insulin sensitivity. METHODS: Sixteen individuals with mean body mass index (BMI) = 29...
June 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28640433/glycemic-improvement-with-a-fixed-dose-combination-of-dpp-4-inhibitor%C3%A2-%C3%A2-metformin-in-patients-with-type-2-diabetes-gift-study
#4
Harpreet S Bajaj, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein, Ronnie Aronson
This study investigates changes in A1C following a switch from dual therapy of metformin and DPP-4 inhibitor to a fixed-dose combination (FDC) of metformin + DPP-4 inhibitor following the introduction of the FDC in the provincial formulary. LMC Diabetes Registry was queried retrospectively for patients with type 2 diabetes, aged between 18-80 years with at least one A1C recorded prior and ≥3 months post-switch. 568 subjects with mean age 64 ± 12 years and mean A1C 7.7% ± 1.2% met study criteria...
June 22, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28640432/favourable-changes-in-mortality-in-people-with-diabetes-u-s-nhanes-1999-2010
#5
Tetsuro Tsujimoto, Hiroshi Kajio, Takehiro Sugiyama
AIMS: Diabetes-related complications have declined during the past two decades. We aimed to examine whether mortality in people with diabetes improved overtime in the 1999-2010 NHANES. METHODS: We conducted a prospective cohort study using 1999-2004 and 2005-2010 data from the National Health and Nutrition Examination Survey. For primary analyses, we compared the unadjusted, age-adjusted, and multivariable-adjusted hazard ratios (HR) for mortality outcomes (total, cardiovascular, cardiac, and cancer deaths) of the participants with diabetes with those without diabetes using Cox proportional hazard models...
June 22, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28636754/linagliptin-and-its-effects-on-hyperglycaemia-and-albuminuria-in-patients-with-type-2-diabetes-and-renal-dysfunction-the-randomized-marlina-t2d%C3%A2-trial
#6
P-H Groop, M E Cooper, V Perkovic, B Hocher, K Kanasaki, M Haneda, G Schernthaner, K Sharma, R C Stanton, R Toto, J Cescutti, M Gordat, T Meinicke, A Koitka-Weber, S Thiemann, M von Eynatten
AIMS: The MARLINA-T2D™ study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria. METHODS: 360 individuals with type 2 diabetes, HbA1c 6.5 - 10.0% (48 - 86 mmol/mol), estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m(2) , and urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g despite single agent renin-angiotensin-system blockade were randomized to double-blind linagliptin (n = 182) or placebo (n = 178) for 24 weeks...
June 21, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28608617/long-term-safety-and-efficacy-of-canagliflozin-as-add-on-therapy-to-teneligliptin-in-japanese-patients-with-type-2-diabetes
#7
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Yumi Watanabe, Maki Gouda, Hiroaki Iijima
AIM: To evaluate the long-term safety and efficacy of canagliflozin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with teneligliptin monotherapy. METHODS: This open-label 52-week study was conducted in Japan. Patients received canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks. The safety endpoint was the incidence of adverse events (AEs). The efficacy endpoints included the changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to week 52 (with last observation carried forward)...
June 13, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28608447/the-effect-of-baseline-characteristics-on-clinical-efficacy-of-liraglutide-in-patients-treated-with-high-dose-insulin
#8
Nagendra Pokala, Beverley Adams-Huet, Xilong Li, Lindsay B Harrison, Anna Vanderheiden, Ildiko Lingvay
In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients' baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables...
June 12, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28605158/the-effect-of-liraglutide-on-dietary-lipid-induced-insulin-resistance-in-humans
#9
Juraj Koska, Lizette Lopez, Karen D'Souza, Tracy Osredkar, James Deer, Julie Kurtz, Arline D Salbe, S Mitchell Harman, Peter D Reaven
AIMS: High saturated fatty acid (SFA) diets blunt peripheral insulin action. GLP-1 receptor agonists suppress postprandial lipids and endothelial dysfunction, which may counter SFA-induced insulin resistance. This study tested whether liraglutide suppresses postprandial elevations in lipids and thus protects against high SFA-diet induced insulin resistance. MATERIALS AND METHODS: In a randomized placebo-controlled cross-over study, 32 subjects with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each...
June 12, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28598577/comment-on-tang-et-al-sodium-glucose-cotransporter-2-inhibitors-and-risk-of-adverse-renal-outcomes-among-type-2-diabetes-patients-a-network-and-cumulative-meta-analysis-of-randomized-controlled-trials-diabetes-obes-metab-2017-doi-10-1111-dom-12917
#10
LETTER
William Canovatchel, Jennifer Davidson, Norm Rosenthal
In a recent article, Tang et al. described the effects of sodium glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus (T2DM) based on a meta-analysis of data from randomized, controlled clinical trials [1]. The authors concluded that among the 3 currently approved SGLT2 inhibitors, dapagliflozin and canagliflozin may be associated with an increased risk of harmful renal outcomes, while empagliflozin may provide benefits on renal function [1].
June 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28598027/a-novel-gip-analog-zp4165-enhances-glp-1-induced-body-weight-loss-and-improves-glycemic-control-in-rodents
#11
P K Nørregaard, M A Deryabina, P Tofteng Shelton, J U Fog, J R Daugaard, P Eriksson, L F Larsen, L Jessen
AIM: To investigate the effects of the novel GIP analog, ZP4165, on body weight and glycemic control in rodents. Additionally, to investigate if ZP4165 modulates the anti-obesity and anti-hyperglycemic effects of a GLP-1 agonist (liraglutide). METHODS: The acute insulinotropic effect of ZP4165 was investigated in rats during an oral glucose tolerance test. Long-term effects of ZP4165 on body weight and glycemic control, either alone or in combination with liraglutide, were assessed in diet-induced obese mice and diabetic db/db mice...
June 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28597588/prevention-of-cardiovascular-disease-by-the-reduction-of-glycemic-exposure-in-type-2-diabetes-a-perspective-on-glucose-lowering-interventions
#12
REVIEW
Ronan Roussel, Philippe Gabriel Steg, Kamel Mohammedi, Michel Marre, Louis Potier
Type 2 diabetes is a leading cause of cardiovascular disease (CVD). Observational studies showed consistently an association between glycemic level and risk of major cardiovascular events (MACE). However, the intervention studies provided limited evidence supporting the reduction of cardiovascular burden of diabetes by intensive glucose control. Here, we propose to apply the concept of cumulative glycemic exposure to protection against CVD in diabetes. We address how we can move from a binary approach in trials, to a more quantitative approach based on differences in cumulative glycemic exposure...
June 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28581253/severe-hypoglycemia-among-patients-with-type-2-diabetes-requiring-emergency-hospital-admission-the-hipos-er-study
#13
João Conceição, Jorge Dores, Francisco Araújo, Pedro Laires, Richard D Carr, Kimberly Brodovicz, Larry Radican, Ana Maria Nogueira
AIMS: In this study we analysed the prevalence of severe hypoglycaemia in patients with type 2 diabetes treated with antihyperglycemic agents (AHA) and requiring emergency room (ER) assistance. This analysis was also done by AHA therapy. MATERIALS AND METHODS: The HIPOS-ER study was a cross-sectional, observational, multicenter, nationwide, study with specific hypoglycemia source data collection. RESULTS: Within the study period, a total of 425,706 admissions were recorded at the ER of participating hospitals...
June 5, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28581209/the-effect-of-continuous-exenatide-infusion-on-cardiac-function-and-perioperative-glucose-control-in-cardiac-surgery-patients-a-single-blind-randomized-controlled-trial
#14
Michal Lipš, Miloš Mráz, Jana Kloučková, Petr Kopecký, Miloš Dobiáš, Jarmila Křížová, Jaroslav Lindner, Michaela Diamant, Martin Haluzík
To intensify perioperative glucose control while minimizing the risk of hypoglycemia and to evaluate the suggested cardioprotective effects of GLP-1-based treatments we performed a randomized controlled trial with the GLP-1 receptor agonist exenatide as add-on to standard perioperative insulin therapy in subjects undergoing elective cardiac surgery. 38 subjects with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective CABG (coronary artery by-pass grafting) were randomized to receive either exenatide or placebo in a continuous 72-hour i...
June 5, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28573777/once-weekly-administration-of-a-long-acting-fgf21-analogue-modulates-lipids-bone-turnover-markers-blood-pressure-and-body-weight-differently-in-obese-hypertriglyceridemic-subjects-and-in-non-human-primates
#15
Albert M Kim, Veena R Somayaji, Jennifer Q Dong, Timothy P Rolph, Yan Weng, Jeffrey R Chabot, Kathryn E Gropp, Saswata Talukdar, Roberto A Calle
AIMS: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting FGF21 analogue, in obese, hypertriglyceridemic subjects on atorvastatin with or without type 2 diabetes. METHODS: Subjects received PF-05231023 or placebo intravenously once-weekly for 4 weeks. Safety (12-lead electrocardiogram [ECGs], vital signs, adverse events [AEs], laboratory tests) and longitudinal weight assessments were performed. Blood samples were collected for pharmacokinetic and pharmacodynamic analyses...
June 1, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28573765/design-and-baseline-characteristics-of-participants-in-the-researching-cardiovascular-events-with-a-weekly-incretin-in-diabetes-rewind-trial-of-dulaglutide-s-cardiovascular-effects
#16
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C Cushman, Edward Franek, Nicolae Hancu, Markolf Hanefeld, Shaun Holt, Petr Jansky, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Ernesto German Cardona Munoz, Valdis Pirags, Nana Pogosova, Peter J Raubenheimer, Jonathan Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev
BACKGROUND: Dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 (GLP1) analogue lowers blood glucose, body weight, appetite, and blood pressure. Its effect on cardiovascular outcomes is unknown. METHODS: People with type 2 diabetes, aged 50 or older, a HbA1c ≤9.5%, and either a previous cardiovascular (CV) event, evidence of CV disease or ≥ 2 CV risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1...
June 1, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28573708/variability-in-and-predictors-of-glycaemic-responses-after-24-weeks-of-treatment-with-exenatide-twice-daily-and-exenatide-once-weekly
#17
Jonathan E Shaw, Baptist Gallwitz, Jenny Han, Elise Hardy, Guntram Schernthaner
The range of glycated haemoglobin (HbA1c) responses and characteristics associated with above-average response to exenatide twice daily (BID) and once weekly (QW) were examined. Data were pooled from 8 exenatide BID and 5 exenatide QW studies. A baseline HbA1c-corrected measure of change in HbA1c after 24 weeks identified high, average, and low responses. Multiple linear regression and multivariate generalized estimating equation models identified factors associated with high response. Among 2355 participants (exenatide BID, n = 1414; exenatide QW, n = 941), baseline HbA1c correlated with change in HbA1c (P<...
June 1, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28573681/projected-long-term-outcomes-in-patients-with-type-1-diabetes-treated-with-fast-acting-insulin-aspart-versus-conventional-insulin-aspart-in-the-uk-setting
#18
D Russell-Jones, S Heller, S Buchs, A Sandberg, W J Valentine, B Hunt
AIMS: Many patients with type 1 diabetes mellitus (T1DM) fail to achieve optimal glycemic control and mealtime insulins that more closely match physiological insulin secretion can help improve treatment. In the onset 1 trial, fast-acting insulin aspart (faster aspart) was shown to improve glycemic control in patients with T1DM compared with conventional insulin aspart (insulin aspart). In the UK, faster aspart and insulin aspart are associated with the same acquisition cost, and therefore the present analysis assessed the impact of faster aspart versus insulin aspart on long-term clinical outcomes and costs for patients with T1DM in the UK setting...
June 1, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28556449/effects-of-metap2-inhibition-on-hyperphagia-and-body-weight-in-prader-willi-syndrome-a-randomized-double-blind-placebo-controlled-trial
#19
Shawn E McCandless, Jack A Yanovski, Jennifer Miller, Cary Fu, Lynne M Bird, Parisa Salehi, Christine L Chan, Diane Stafford, M Jennifer Abuzzahab, David Viskochil, Sarah E Barlow, Moris Angulo, Susan E Myers, Barbara Y Whitman, Dennis Styne, Elizabeth Roof, Elisabeth M Dykens, Ann O Scheimann, Jaret Malloy, Dongliang Zhuang, Kristin Taylor, Thomas E Hughes, Dennis D Kim, Merlin G Butler
AIMS: There are no treatments for the extreme hyperphagia and obesity in Prader-Willi syndrome (PWS). The bestPWS trial assessed the efficacy, safety, and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. MATERIALS AND METHODS: Participants with PWS (12-65 years) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib, or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Coprimary endpoints were the changes in hyperphagia (measured by Hyperphagia Questionnaire for Clinical Trials [HQ-CT]; possible score 0-36) and weight by intention-to-treat...
May 29, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28544245/ghrelin-receptor-inverse-agonists-as-a-novel-therapeutic-approach-against-obesity-related-metabolic-disease
#20
Kathrin Abegg, Lara Bernasconi, Melanie Hutter, Lynda Whiting, Claudio Pietra, Claudio Giuliano, Thomas A Lutz, Thomas Riediger
AIMS: Ghrelin is implicated in the control of energy balance and glucose homeostasis. The ghrelin receptor exhibits ligand independent constitutive activity, which can be pharmacologically exploited to induce inverse ghrelin actions. Since ghrelin receptor inverse agonists (GHSR-IA) might be effective for the treatment of obesity-related metabolic disease, we tested two novel synthetic compounds GHSR-IA1 and GHSR-IA2. MATERIALS AND METHODS: In functional cell assays, electrophysiogical and immunohistochemical experiments, we demonstrated inverse agonist activity for GHSR-IA1 and GHSR-IA2...
May 24, 2017: Diabetes, Obesity & Metabolism
journal
journal
34603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"